Drug class
Hydrolytic Lysosomal Cholesteryl Ester-specific Enzyme
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
Home→ERA Profiles → Sebelipase Alfa→
Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
Hydrolytic Lysosomal Cholesteryl Ester-specific Enzyme
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
ReguSight provides project-specific support for the Sebelipase Alfa Environmental Risk Assessment (ERA) (the Sebelipase Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.